Skip to content Skip to sidebar Skip to footer
Subscribe Now
Biopharma Deal Terminations Top 20 2018 - 19
TOP 20

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a list of…
January 3, 20200Comments

Read more

Formats

The Blues Kitchen Podcast

Q ed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium loremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. …
January 1, 20200Comments

Read more

Insights+ Key Biosimilars Events of November 2019
INSIGHTS+

Insights+ Key Biosimilars Events of November 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar…
December 6, 20190Comments

Read more

Biosimilar Companies Top 20 2018
TOP 20

Top Biosimilar Companies with Approved and Pipeline Products in the US and EU

​Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics possessing similar therapeutic properties in terms of potency- safety- and efficacy to original biologic products. The companies are focusing…
November 29, 20190Comments

Read more

Octavus Consulting Collaborates with IBCI for Delivering of Professional Educational Programs in India from 2020
INSIGHTS+

Octavus Consulting Collaborates with IBCI for Delivering of Professional Educational Programs in India from 2020

Shots:The IBCI educational programs will focus on providing perspectives on Business & Competitive Intelligence role in every industry for professionals from all domains in India. Additionally, IBCI has already provided 50 types of programs for 7000+ highly qualified professionals from every domainOctavus Consulting with its team expertise in Competitive Intelligence and Product Strategies…
November 28, 20190Comments

Read more

PharmaShots Interview: AstraZeneca's Global Medicine Leader John Houghton Shares Insights on Roxadustat in Treating Patients with Anemia Due to CKD at ASN 2019
VIEWPOINTS

PharmaShots Interview: AstraZeneca’s Global Medicine Leader John Houghton Shares Insights on Roxadustat in Treating Patients with Anemia Due to CKD at ASN 2019

AstraZeneca presented P-III data of Roxadustat along with unprecedented 41 abstracts from its renal portfolio at American Society of Nephrology Kidney Week 2019, demonstrating its commitment to advancing the care of Chronic Kidney Diseases (CKD) and its complications, affecting millions of people across the globe.On Nov 12, 2019 in an interview with PharmaShots, John…
November 12, 20190Comments

Read more